UBS Global Biopharma Conference, London, November 17, 2026

Royalty Pharma executives told the UBS Global Biopharma Conference that co-funding R&D programs at large pharmaceutical companies is set to become a bigger part of the company's growth profile, helped by a US GAAP change that allows contra-R&D accounting. Christopher Hite, Chairman of Partnering and Investments, and Greg Butz, EVP of Partnering, spoke with UBS analyst Ashwani Verma shortly after the company reported third-quarter results, which Hite described as another beat and raise.

Contra-R&D accounting is pulling large pharma into the model

Hite said the opportunity set with large pharma is both large and accelerating, and he pointed first to the accounting. "US GAAP now clearly allows contra-R&D accounting," he said, explaining that a $0.5 billion deal with a large pharmaceutical company "allows them to spend $0.5 billion more on pipeline and maintain the same level of EPS." In his words: "What head of R&D at large pharma wouldn't want to spend another $0.5 billion on their pipeline? Everyone wants to."

Hite cited J&J, Pfizer, Merck, Biogen, Teva and Sanofi as companies that have done transactions with Royalty Pharma. He said their activity is prompting peers to take notice: "It's almost feeding upon itself." Competitors see these companies expanding R&D spend without changing reported R&D expense, he said, and conclude they need to investigate the structure. He added that Royalty Pharma's passive role is a draw, since it does not sit on joint development committees or joint steering committees, and that the arrangement lets pharma share risk on an asset. "I think it's just really the beginning," Hite said.

Butz framed the opportunity as covering both the assets already in big pharma and biotech R&D portfolios and those that enter through business development or M&A. He said Royalty Pharma has the financial scale to write investments of multiple hundreds of millions of dollars or more than $1 billion, and that deployment numbers should rise over time as large-company R&D budgets grow.

China is positioned as incremental to the capital deployment target

Butz said management views China "as in addition to our stated capital deployment goals," describing the opportunity as relatively nascent. It centers on passive royalties created as Western multinationals license assets from Chinese innovators, with those assets now maturing through Phase II and Phase III in big pharma hands.

Hite said Royalty Pharma hired Ken Sun, formerly head of Morgan Stanley's health care practice in Asia, this year to lead its China effort. Chinese licensors have often negotiated attractive royalties on products that are approved, he said, and the company is tracking those products at the large pharmaceutical companies while telling Chinese companies of its interest. He pointed to last year's roughly $900 million purchase of a royalty stream held by BeOne, which has Chinese origins, on Amgen's product as a deal that "really caught the attention of the Chinese innovators." Hite said the company has to follow the development of these products at Western multinationals and that "when the time is right," there should be a "very nice opportunity set there."

Why synthetic royalties have moved into the mainstream

Hite described the company as 30 years old, public since 2020 and investment-grade rated, with publicly stated capital deployment goals of $2 billion to $2.5 billion a year. Last year it reviewed 480 opportunities and completed about 7 deals, with roughly $4.7 billion of announced transaction value. He said the pace this year could be higher.

He attributed the growth of synthetic royalties, which fund R&D and launches rather than buy existing streams, to the financing terms. Using the Revolution Medicines deal of up to $2 billion as an example, he said the company, then at roughly an $8 billion market cap, could have raised equity or convertibles or partnered its assets in the US or ex-US. A synthetic royalty lets it avoid partnering. Hite argued that the cost of capital compares favorably with equity, given how the stock has performed since the deal. He added that Royalty Pharma is a passive partner with no joint committees, no restrictive covenants and no giving away of regional rights....